ARTICLE | Company News
Novartis in-licenses GenVec's hearing loss program
January 20, 2010 2:32 AM UTC
GenVec Inc. (NASDAQ:GNVC) gained $0.20 (12%) to $1.94 on Tuesday after granting Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to its preclinical hearing loss and balance disorders progr...